Drug class review : final reportDirect renin inhibitors, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers / Susan Norris, Jessica Weinstein, Kimberly Peterson, Sujata Thakurta ; Drug Effectiveness Review Project, Marian McDonagh, prinicipal investigator ; Oregon Evidence-based Practice Center, Mark Helfand, director ; Oregon Health & Science University
The renin-angiotensin system is a complex biologic system between the heart, brain, blood vessels, and kidneys that leads to the production of biologically active agents, including angiotensin I and II and aldosterone, which act together to impact a variety of bodily functions including blood vessel tone, sodium balance, and glomerular filtration pressure. The multiple and varied effects of these agents allows the renin-angiotensin system to play a wide role in the pathology of hypertension, cardiovascular health, and renal function. Our ability to begin to intervene upon the complex cycle of hormone and other biochemical agent production within the renin-angiotensin system began with the advent of the first orally active ACE-I (angiotensin converting enzyme inhibitor), captopril, in 1981. AIIRAs (angiotensin II receptor blockers) were developed as an alternative to ACE-I, and block the interaction between angiotensin II and the angiotensin receptor. Losartan, the first commercially available AIIRA, was approved for clinical use in 1995. The goal of this report is to compare the effectiveness and harms between aliskiren and placebo and between AIIRAs and ACEIs in the treatment of diagnosed coronary heart disease, hypertension, left ventricular dysfunction, heart failure, nondiabetic chronic kidney disease, or diabetic nephropathy..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
Portland, Oregon: Oregon Health & Science University ; 2010 |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Norris, Susan L. [VerfasserIn] |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Angiotensin Receptor Antagonists |
|---|
| Anmerkungen: |
"January 2010.". - Title from PDF t.p. - Includes bibliographical references. - Description based on version viewed December 7, 2013 |
|---|
| Umfang: |
1 online resource (1 PDF file (144 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773228161 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773228161 | ||
| 003 | DE-627 | ||
| 005 | 20230427041627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2010 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773228161 | ||
| 035 | |a (DE-599)KEP068667221 | ||
| 035 | |a (NCBI)9916183333406676 | ||
| 035 | |a (EBP)068667221 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Norris, Susan L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug class review |b final reportDirect renin inhibitors, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers |c Susan Norris, Jessica Weinstein, Kimberly Peterson, Sujata Thakurta ; Drug Effectiveness Review Project, Marian McDonagh, prinicipal investigator ; Oregon Evidence-based Practice Center, Mark Helfand, director ; Oregon Health & Science University |
| 264 | 1 | |a Portland, Oregon |b Oregon Health & Science University |c 2010 | |
| 300 | |a 1 online resource (1 PDF file (144 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Drug class reviews | |
| 500 | |a "January 2010.". - Title from PDF t.p. - Includes bibliographical references. - Description based on version viewed December 7, 2013 | ||
| 520 | |a The renin-angiotensin system is a complex biologic system between the heart, brain, blood vessels, and kidneys that leads to the production of biologically active agents, including angiotensin I and II and aldosterone, which act together to impact a variety of bodily functions including blood vessel tone, sodium balance, and glomerular filtration pressure. The multiple and varied effects of these agents allows the renin-angiotensin system to play a wide role in the pathology of hypertension, cardiovascular health, and renal function. Our ability to begin to intervene upon the complex cycle of hormone and other biochemical agent production within the renin-angiotensin system began with the advent of the first orally active ACE-I (angiotensin converting enzyme inhibitor), captopril, in 1981. AIIRAs (angiotensin II receptor blockers) were developed as an alternative to ACE-I, and block the interaction between angiotensin II and the angiotensin receptor. Losartan, the first commercially available AIIRA, was approved for clinical use in 1995. The goal of this report is to compare the effectiveness and harms between aliskiren and placebo and between AIIRAs and ACEIs in the treatment of diagnosed coronary heart disease, hypertension, left ventricular dysfunction, heart failure, nondiabetic chronic kidney disease, or diabetic nephropathy. | ||
| 650 | 2 | |a Angiotensin-Converting Enzyme Inhibitors |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D000806Q000627 | |
| 650 | 2 | |a Angiotensin Receptor Antagonists |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D057911Q000627 | |
| 650 | 2 | |a Renin-Angiotensin System |x drug effects |0 https://id.nlm.nih.gov/mesh/D012084Q000187 | |
| 655 | 2 | |a Review |0 https://id.nlm.nih.gov/mesh/D016454 | |
| 700 | 1 | |a Weinstein, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Peterson, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Thakurta, Sujata |e verfasserin |4 aut | |
| 700 | 1 | |a McDonagh, Marian S. |e verfasserin |4 aut | |
| 710 | 2 | |a Drug Effectiveness Review Project, |e MitwirkendeR |4 ctb | |
| 710 | 2 | |a Oregon Health & Science University. |b Evidence-based Practice Center, |e VerfasserIn |4 aut | |
| 710 | 2 | |a Oregon Health & Science University, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK47119/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994124247 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994050537 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999827149 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995720323 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987718781 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987807644 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK47119/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK47119/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK47119/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK47119/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK47119/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||